| Adaptive landscape by environment interactions dictate evolutionary dynamics in models of drug resistance CB Ogbunugafor, CS Wylie, I Diakite, DM Weinreich, DL Hartl PLoS computational biology 12 (1), e1004710, 2016 | 92 | 2016 |
| Time from infection to disease and infectiousness for Ebola virus disease, a systematic review GE Velásquez, O Aibana, EJ Ling, I Diakite, EQ Mooring, MB Murray Clinical Infectious Diseases 61 (7), 1135-1140, 2015 | 66 | 2015 |
| Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic … R Liu, OO Oluwole, I Diakite, MF Botteman, JT Snider, FL Locke Journal of Medical Economics 24 (1), 458-468, 2021 | 30 | 2021 |
| Cost effectiveness of vericiguat for the treatment of chronic heart failure with reduced ejection fraction following a worsening heart failure event from a US Medicare perspective A Alsumali, LM Djatche, A Briggs, R Liu, I Diakite, D Patel, Y Wang, ... Pharmacoeconomics 39, 1343-1354, 2021 | 25 | 2021 |
| A mathematical model of bone remodeling with delays BM Chen-Charpentier, I Diakite Journal of computational and applied mathematics 291, 76-84, 2016 | 23 | 2016 |
| Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of … OO Oluwole, R Liu, I Diakite, C Feng, A Patel, I Nourhussein, JT Snider, ... Journal of Medical Economics 25 (1), 541-551, 2022 | 10 | 2022 |
| Novel ordered stepped-wedge cluster trial designs for detecting Ebola vaccine efficacy using a spatially structured mathematical model I Diakite, EQ Mooring, GE Velásquez, MB Murray PLoS Neglected Tropical Diseases 10 (8), e0004866, 2016 | 6 | 2016 |
| Improving a fuel cell assembly process I Diakite, DA Edwards, B Emerick, M Panaggio, AL Peace, C Raymond, ... Mathematics-in-Industry Case Studies 6 (1), 2014 | 5 | 2014 |
| Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis BG Schultz, I Diakite, JA Carter, SJ Snedecor, R Turpin Journal of Managed Care & Specialty Pharmacy 27 (11), 1592-1600, 2021 | 4 | 2021 |
| Indirect Treatment Comparison of Venetoclax plus Rituximab with B-cell Receptor Inhibitors in Patients with Relapsed/Refractory Chronic Lymphocytic Leukaemia A Mato, G Follows, K Sail, I Diakite, D Nicoloso, B Dietz, J Maher, ... British journal of haematology 185, 91-92, 2019 | 3 | 2019 |
| Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV … I Diakite, S Nguyen, U Sabale, A Pavelyev, K Saxena, AA Tajik, W Wang, ... Journal of Medical Economics 26 (1), 1085-1098, 2023 | 2 | 2023 |
| Structured Literature Review to Identify Human Papillomavirus’s Natural History Parameters for Dynamic Population Models of Vaccine Impacts I Diakite, B Martins, K Owusu-Edusei, C Palmer, O Patterson-Lomba, ... Infectious Diseases and Therapy, 1-26, 2024 | 1 | 2024 |
| Public health impact of 2-, 4-, and 9-valent HPV vaccination in females on cervical and noncervical diseases in men and women under different coverage scenarios in China: A … I Diakite, J Kyle, S Situ, P Bai, X Zhang, W Wang, V Daniels Human Vaccines & Immunotherapeutics 19 (2), 2258569, 2023 | 1 | 2023 |
| EPH42 Evaluating the Public Health Impact of Dengue Vaccination in Indonesia: A Dynamic Transmission Modeling Assessment amidst Uncertainties in the Implementation Strategies S Garba, YH Chen, J Lang, D Wang, I Diakite, C Palmer, E Elbasha Value in Health 27 (6), S160, 2024 | | 2024 |
| COST-EFFECTIVENESS OF VEDOLIZUMAB IV VERSUS ADALIMUMAB SC FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS R Schultz, I Diakite, JA Carter, S Snedecor, RS Turpin GASTROENTEROLOGY 158 (6), S658-S658, 2020 | | 2020 |
| Cost-effectiveness of vedolizumab SC vs. adalimumab for moderately to severely active ulcerative colitis I Diakite, B Schultz, J Carter, S Snedecor, R Turpin JOURNAL OF CROHNS & COLITIS 14, S454-S455, 2020 | | 2020 |
| Cost-effectiveness of vedolizumab IV vs. adalimumab SC for moderately to severely active ulcerative colitis R Schultz, I Diakite, J Carter, S Snedecor, R Turpin JOURNAL OF CROHNS & COLITIS 14, S508-S508, 2020 | | 2020 |
| PB1782 TWO‐YEAR SURVIVAL WITH AXICABTAGENE CILOLEUCEL IN RELAPSED OR REFRACTORY LARGE B‐CELL LYMPHOMA: AN UPDATED ANALYSIS I Diakite, VW Lin, S Klijn, L Navale, AG Purdum, E Fenwick, M Botteman, ... HemaSphere 3, 817, 2019 | | 2019 |
| MS2 AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL) I Diakite, VW Lin, S Klijn, L Navale, AG Purdum, E Fenwick, M Botteman, ... Value in Health 22, S41, 2019 | | 2019 |
| Effects of Discrete Time Delays and Parameters Variation on Dynamical Systems IO Diakite, B Chen-Charpentier Biomath 4 (1), ID: 1505201-ID: 1505201, 2015 | | 2015 |
